X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN LTD TORRENT PHARMA/
LUPIN LTD
 
P/E (TTM) x 44.8 30.0 149.3% View Chart
P/BV x 6.1 2.9 212.0% View Chart
Dividend Yield % 0.8 0.6 145.6%  

Financials

 TORRENT PHARMA   LUPIN LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
LUPIN LTD
Mar-18
TORRENT PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,5501,465 105.8%   
Low Rs1,144727 157.3%   
Sales per share (Unadj.) Rs354.7349.6 101.5%  
Earnings per share (Unadj.) Rs40.15.6 721.0%  
Cash flow per share (Unadj.) Rs64.229.6 217.1%  
Dividends per share (Unadj.) Rs14.005.00 280.0%  
Dividend yield (eoy) %1.00.5 227.9%  
Book value per share (Unadj.) Rs273.1300.3 91.0%  
Shares outstanding (eoy) m169.22452.08 37.4%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.83.1 121.1%   
Avg P/E ratio x33.6197.2 17.0%  
P/CF ratio (eoy) x21.037.1 56.6%  
Price / Book Value ratio x4.93.6 135.1%  
Dividend payout %34.990.0 38.8%   
Avg Mkt Cap Rs m227,897495,502 46.0%   
No. of employees `00014.717.0 86.3%   
Total wages/salary Rs m11,35328,647 39.6%   
Avg. sales/employee Rs Th4,083.09,273.6 44.0%   
Avg. wages/employee Rs Th772.31,681.0 45.9%   
Avg. net profit/employee Rs Th461.3147.4 312.9%   
INCOME DATA
Net Sales Rs m60,021158,042 38.0%  
Other income Rs m2,9881,504 198.8%   
Total revenues Rs m63,009159,545 39.5%   
Gross profit Rs m13,49331,475 42.9%  
Depreciation Rs m4,08610,859 37.6%   
Interest Rs m3,0852,044 151.0%   
Profit before tax Rs m9,31020,076 46.4%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m2,5292,885 87.7%   
Profit after tax Rs m6,7812,513 269.9%  
Gross profit margin %22.519.9 112.9%  
Effective tax rate %27.214.4 189.0%   
Net profit margin %11.31.6 710.7%  
BALANCE SHEET DATA
Current assets Rs m52,623122,095 43.1%   
Current liabilities Rs m52,02250,956 102.1%   
Net working cap to sales %1.045.0 2.2%  
Current ratio x1.02.4 42.2%  
Inventory Days Days12085 141.4%  
Debtors Days Days76120 63.6%  
Net fixed assets Rs m85,016129,876 65.5%   
Share capital Rs m846904 93.6%   
"Free" reserves Rs m45,376134,866 33.6%   
Net worth Rs m46,222135,771 34.0%   
Long term debt Rs m41,11564,245 64.0%   
Total assets Rs m142,432263,054 54.1%  
Interest coverage x4.010.8 37.1%   
Debt to equity ratio x0.90.5 188.0%  
Sales to assets ratio x0.40.6 70.1%   
Return on assets %6.91.7 399.9%  
Return on equity %14.71.9 792.8%  
Return on capital %14.23.7 381.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58053,141 27.4%   
Fx outflow Rs m3,60019,335 18.6%   
Net fx Rs m10,98033,807 32.5%   
CASH FLOW
From Operations Rs m8,94217,512 51.1%  
From Investments Rs m-47,070-14,073 334.5%  
From Financial Activity Rs m34,174-14,921 -229.0%  
Net Cashflow Rs m-3,655-11,482 31.8%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS